Unidiag Completed Its Series A+ Round

China Announced The World’s Second Largest Medical Device Market
December 22, 2017
Transenterix Forges a Local Partnership to Commercialize Its SurgiBot System in China
December 27, 2017

Unidiag Completed Its Series A+ Round

Beijing Unidiag Technology Co., Ltd, a Chinese medical device and reagent developer, has raised 10M+ RMB in Series A+ round from National Small and Medium-size Enterprises Development Fund (Shenzhen Guozhong Venture Capital Management Co., Ltd). Shenzhen Ronghaoda Investment Co., Ltd, and Tehua Investment Holding Co., Ltd also took part in the round. The company is specialized in the field of chemiluminescence immunoassay analyzer and reagent.

 

Unidiag Inc was founded in USA with a mission to deliver cost effective medical devices and reagents. Specialized in the field of Chemiluminescence Immunoassay Analyzer and reagent, Ultrasound machine´╝îits leading medical device &reagent research and development infrastructure in both America and China.

 

Around 50% of research and development team member hold Masters or Doctorate degrees. To enhance our market position, they have made and will continue to make significant investments in research and development. In fact, we invest approximately 18% of net revenues every year in research and development activities even as net revenues continue to experience strong growth. POCT products and related reagents, such as rapid test, Dry biochemical analyzer, dry-type blood cell analyzer and hematology analyzer will be coming soon. They applied Electro-chemiluminescence PCT patent. Meanwhile, Electro-chemiluminescence patent has got approval in USA ,China, Japan, Korea and other countries.